The FDA announced on September 13, 2019, that low levels of a probable human carcinogen called N-nitrosodimethlylamine (NDMA), were found in Zantac (ranitidine).
As a result, major drugstores such as Walgreens and CVS have taken all generic versions of ranitidine and Zantac off their shelves until further notice from the FDA.
Drug manufacturers, Sandoz (a division of Novartis) and Apotex have also decided to take action and are recalling all of their generic ranitidine drugs that are sold in the United States.
The FDA is working with multiple international agencies to review the medications and to determine if the impurities pose a health risk to users.
The agency is also asking ranitidine manufacturers to perform tests on their individual products and to send samples to the FDA for additional examinations.
Drug Recall
Who is online
Users browsing this forum: No registered users and 32 guests